Immunovant, Inc. IMVT
29.04 USD +0.63 (+2.22%)
At closeNov 3, 2026, 4:01 PM EST
29.04 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
28.42 Day range 29.48
21.43 52-week range 45.42
- YTD
- +14.24%
- 1 year
- +22.12%
Analyst view
Consensus: buy
Buy
Price target (mean) 48.88 +68.3% upside
Now 29.04
- Target (low)
- 30.00
- Target (mean)
- 48.88
- Target (high)
- 66.00
Ratings (0m) 17 13 buy · 4 hold · 0 sell
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.72212 | -0.75751 – -0.69886 | -0.6482 | -11.4% | 0 | 0.0% | 3 |
| Next quarter | -0.67107 | -0.76971 – -0.53349 | -0.5373 | -24.9% | 0 | 0.0% | 3 |
| Current year | -2.84 | -3.05 – -2.52 | -2.47 | -15.1% | 0 | 0.0% | 5 |
| Next year | -2.75 | -3.21 – -2.38 | -2.84 | +3.2% | 36.81M | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 30, 2026 | Citigroup | Maintained | Buy | Buy |
| May 26, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 22, 2026 | Truist Securities | Maintained | Hold | Hold |
| May 21, 2026 | B of A Securities | Maintained | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 15, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 8, 2026 | Truist Securities | Maintained | Hold | Hold |
| Jan 6, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Dec 15, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 14, 2025 | Truist Securities | Initiated | — | Hold |
| Sep 30, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 4, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 12, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jul 28, 2025 | UBS | Maintained | Neutral | Neutral |
| Apr 22, 2025 | UBS | Downgrade | Buy | Neutral |
| Mar 20, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Mar 20, 2025 | B of A Securities | Maintained | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Maintained | Buy | Buy |
| Feb 10, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 7, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 15, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jan 3, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Dec 19, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
